» Articles » PMID: 32775312

Granulocyte Colony Stimulating Factor Ameliorates Hepatic Steatosis Associated with Improvement of Autophagy in Diabetic Rats

Overview
Specialty Gastroenterology
Date 2020 Aug 11
PMID 32775312
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We previously reported that the granulocyte colony stimulating factor (G-CSF) ameliorated hepatic steatosis with the enhancement of -oxidation-related gene expression. However, the mechanisms underlying this process remain unclear. This study aimed to determine whether the improvement of hepatic steatosis by G-CSF was associated with autophagy in a rat model of diabetes.

Methods: Eight rats were fed a standard diet, and 16 rats were fed high-fat diet (HFD) for 5 weeks. All HFD-fed rats were then injected with streptozotocin (STZ). One week later, HFD rats injected with STZ were randomly treated with either G-CSF (200 g/kg/day; diabetes mellitus (DM)/G-CSF) or saline (DM/saline) for 5 consecutive days. Four weeks later, serum biochemical and histology analyses were conducted. The expression of autophagy-associated proteins was determined by Western blotting. The mRNA expression of -oxidation-related genes was determined by quantitative real-time polymerase chain reaction. HepG2 cells were cultured under high glucose (HG) conditions with G-CSF treatment, followed by Oil Red O staining for quantification of lipids.

Results: Histological analysis showed lower lipid accumulation in the DM/G-CSF group than in the DM/saline-treated rats. Protein levels of LC3 and beclin-1 were higher, and those of p62 were lower in the DM/G-CSF rats than in the DM/saline-treated rats. The mRNA expression of -oxidation-related genes was higher in DM/G-CSF rats than in the DM/saline-treated rats. Quantification of lipid levels in HepG2 cells cultured with HG and G-CSF treatment revealed no significant differences.

Conclusions: Our data suggested that G-CSF potentially improves hepatic steatosis and autophagy in the liver of diabetic rats.

References
1.
Rector R, Thyfault J, Wei Y, Ibdah J . Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008; 14(2):185-92. PMC: 2675112. DOI: 10.3748/wjg.14.185. View

2.
Mavrogiannaki A, Migdalis I . Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol. 2013; 2013:450639. PMC: 3638654. DOI: 10.1155/2013/450639. View

3.
Marceau P, Biron S, Hould F, Marceau S, Simard S, Thung S . Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999; 84(5):1513-7. DOI: 10.1210/jcem.84.5.5661. View

4.
Spahr L, Lambert J, Rubbia-Brandt L, Chalandon Y, Frossard J, Giostra E . Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology. 2008; 48(1):221-9. DOI: 10.1002/hep.22317. View

5.
Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J . Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95. DOI: 10.1002/hep.20466. View